Bayer raises sales and earnings

  • Group sales increase by 2.3% (Fx & portfolio adj.) to €11.8 billion
  • Pharmaceuticals continues strong growth trend
  • Consumer Health increases sales
  • Crop Science business holds steady in a continuingly difficult market environment
  • EBITDA before special items up 5.7% to €3.1 billion
  • Net income €1.4 billion (+18.6%)
  • Core earnings per share €2.07 (+4.0%)
  • Group forecast raised

The Bayer Group posted further growth in the second quarter of 2016. Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales increased by 2.3% to €11.8 billion and EBITDA before special items by 5.7% to €3.1 billion. The Life Sciences recorded encouraging sales and earnings growth overall. At Pharmaceuticals, we benefited from the continued strong development of our recently launched products. Consumer Health increased sales, while EBITDA before special items receded. Sales of Crop Science held steady at the prior-year level despite a continuingly difficult market environment, while earnings decreased. EBITDA before special items at Animal Health declined despite sales growth. Covestro registered a substantial increase in EBITDA before special items, while sales fell as expected. We are raising the Group forecast.